Abbott beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices ...

Continuous glucose monitor makers such as Abbott, Dexcom and Medtronic are riding a surge in demand as diabetes awareness ...

Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2025, ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign aid freeze.

Medical device sales remained a bright spot for the company, however, with more than 20% growth in diabetes devices.

Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...

For the current quarter ending in September, Abbott expects its per-share earnings to range from $1.28 to $1.32. The company ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its medical devices, ...